Scienture Holdings Inc (MEDS) FinancialsMEDSFinancialScienture Holdings Inc

DataMeds AI Inc (MEDS) generates its revenue primarily from Integra pharma, LLC, which accounts for 100.0% of total sales, equivalent to $18.70K. Understanding this concentration is critical for investors evaluating how MEDS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, DataMeds AI Inc maintains a gross margin of -9.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -412.68%, while the net margin is -1031.72%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MEDS converts its operational activities into shareholder value.

In the context of the broader market, MEDS competes directly with industry leaders such as RDGT and JWEL. With a market capitalization of $2.94M, it holds a significant position in the sector. When comparing efficiency, MEDS's gross margin of -9.80% stands against RDGT's 3.92% and JWEL's 8.16%. Such benchmarking helps identify whether DataMeds AI Inc is trading at a premium or discount relative to its financial performance.

TRxADE Health Inc has shown poor financial performance, with total revenue peaking at $12,410,423 in Q4 2024 but followed by severe losses, including a net income loss of -$34,318,204 in Q3 2025. The gross margin has been negative for several quarters, indicating challenges in profitability.